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Introduction: Chagas disease (CD) is a worldwide problem, with over 8 million people infected in 
both rural and urban areas. CD was first described over a century ago, but only two drugs are 
currently available for CD treatment, benznidazole (BZN) and nifurtimox (NF). Treating CD infected 
patients, especially children and women of reproductive age, is vital in order to prevent long term 
sequelae, such as heart and gastrointestinal dysfunction, but this aim is still far from being 
accomplished. Currently, the strongest data to support benefit-risk considerations come from 
trials in children. Finally, treatment response biomarkers need further development as serology is 
being questioned as the best method to assess treatment response.  
Areas covered: This article is a narrative review on the pharmacology of drugs for CD, particularly 
BZN and NF. Data on drug biopharmaceutical characteristics, safety and efficacy of both drugs are 
summarized from a clinical perspective. Current data on alternative compounds under evaluation 
for CD treatment, and new possible treatment response biomarkers are also discussed.  
Conclusion: Early diagnosis and treatment of CD, especially in pediatric patients, is vital for an 
effective and safe use of the available drugs (i.e. BZN and NF). New biomarkers for CD are urgently 
needed for the diagnosis and evaluation of treatment efficacy, and to guide efforts from academia 
and pharmaceutical companies to accelerate the process of new drugs development.  
 
  




Chagas disease (CD) is a zoonosis caused by infection with Trypanosoma cruzi, a protozoan 
parasite. Humans can acquire this infection by contact with insect vectors (hematophagous 
triatomine or Reduviidae bugs), by ingestion of contaminated food1, congenital transmission, 
blood transfusions or organ or tissue transplants from infected donors. In the past, CD was 
believed to exclusively affect rural populations in Latin America, but movement of people from 
rural to urban areas (as well as expanding screening strategies to urban dwellers), has revealed the 
infection as a worldwide problem2,3. Congenital transmission in particular has become an 
important route of infection and the main reason for acute CD in non-endemic countries, such as 
North America and Europe.  
The World Health Organization (WHO) estimates that over 8 million people worldwide are 
infected with T cruzi, and that an excess of 10,000 deaths occur every year due to CD 2. Under-
diagnosis of CD cases is suspected to be as high as 90%, and even higher in cases of congenital CD 
which is alarming considering that estimated T. cruzi prevalence among pregnant women ranges 
from 2% to 40% depending on geographical area 4,5.  
CD has a clinical course characterized by an acute phase, commonly asymptomatic, that 
resolves spontaneously in most cases but which can sometimes (i.e. less than 5% of cases) be 
severe, leading to serious sequelae and even death. Following the acute phase, a chronic stage 
ensues, with patients usually remaining asymptomatic for many decades. However, approximately 
30% of infected patients eventually develop progressive and irreversible target organ damage, 
mainly in the heart and/or esophagus and colon. The ‘silent’ asymptomatic phase between acute 
and chronic phases is referred to as ‘indeterminate stage’ by some authors.6,7  
The decision to implement CD treatment was historically based on age, due to limited 
evidence of efficacy, and an increasing frequency and severity of side effects in relation to patient 
age. 8 Currently there is agreement in international clinical guidelines that anti-parasitic treatment 
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is effective and therefore should be offered at least to 1) patients with acute CD, 2) all children 
with congenital or acquired acute CD 3) immunosuppressed hosts with acute or reactivation of 
chronic disease 4) women of childbearing age in order to prevent congenital transmissions 9–12.   
Treatment effectiveness in chronic CD continues to be highly debated 13–15; for adults over 
50 years old, trypanocidal therapy is still considered optional due to an unclear risk-benefit 
balance. On the one hand there is a general agreement that parasitic persistence increases the risk 
for development or progression of cardiac lesions in chronically infected patients and therefore 
parasite eradication may be necessary in the early stages of the disease16,17. On the other hand, 
advanced CD seems to involve irreversible cardiac damage, and therefore parasiticidal treatment 
of affected older patients may be futile13. However, the evidence for either position is still 
limited18. 
Unfortunately, anti-parasitic therapy has not been widely implemented, even for those 
age groups that can clearly benefit from it (e.g. pediatric patients, early chronic infections, etc.) in 
spite of existing national and international guidelines that support treatment. This failure to treat 
may possibly be explained by many obstacles, including health care providers’ low awareness of 
CD and its treatment options, overblown concerns about side effects, low access to healthcare for 
many patients with CD, lack of an optimal straightforward test of CD cure, widespread drug 
shortages and irregular supplies, and regulatory barriers19. Even though WHO 2020 Goals for CD 
included access to treatment and/or care of all infected/ill patients, and The London Declaration 
on Neglected Tropical Diseases 20 announced plans for the elimination or control of Chagas disease 
by 2020, current estimates indicate that less than 1% of CD infected patients are treated and those 
lofty aims are far away from becoming a reality.21 Sub-optimal CD treatment implementation 
continues in many countries in spite the fact that failing to treat a CD patient could be considered 
medical negligence in many jurisdictions22.  
In South America, CD causes the loss of over 750,000 working days because of premature 
deaths and $1.2 billion in productivity loss every year 23. The calculated annual global burden of 
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disease is over $600 million dollars per year in health-care costs and 10% of this burden affects 
non-endemic countries24. According to a study conducted in Mexico that evaluated the impact and 
economic outcomes (costs, cost-effectiveness, cost-benefit) of identifying and treating different 
percentages of CD patients in the acute and indeterminate phases, identifying and treating CD 
cases earlier was always economically dominant compared to no treatment21. Authorities in 
charge of health policies should acknowledge that this would result not only in reduced 
transmission rates and better health outcomes but also in huge cost-savings, besides being a 
medical duty, and human rights issue. 
Despite the fact that CD was first described over a century ago25, only two drugs are 
currently available for treatment, benznidazole (BZN) and nifurtimox (NF), which were developed 
over 40 years ago. Both drugs require prolonged treatments (30 to 60 days) and are associated 
with adverse events that increase in severity and prevalence with age. Prompt diagnosis and 
treatment, especially in pediatric patients, are vital for an effective use of these medications.  
 
PHARMACOLOGICAL TREATMENT OF CD 
Both NF and BZN are nitroheteroerocyclic drugs developed over four decades ago by Bayer 
and Roche, respectively. Their mechanism of action is believed to rely on intracellular activation, 
that generates intermediates affecting the parasite’s vital biological functions 26,27. Both drugs are 
highly liposoluble, with very low water solubility. The parasite`s mechanisms against these drugs 
relies on detoxifying molecules such as trypanothione 28 a vital part of the free radical scavenging 
cycle that is recycled by the enzyme trypanothione disulfide reductase.  
Treatment with BZN and NF is contraindicated during pregnancy in most guidelines, due to 
limited evidence on safety, yet there is evidence of low concentration of BZN or NF in breastmilk 
with no risk to infants during lactation 29–31.  
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These drugs are usually not recommended in patients with renal or hepatic impairment, 
mostly on the basis of lack of safety data. However, given that these drugs are almost completely 
metabolized, renal elimination only plays a marginal role in their clearance and use in kidney 
failure would be possible with appropriate monitoring for adverse events. Similarly, in cases 
requiring emergency treatment (e.g. CD meningoencephalitis), hepatic impairment should not be 
an obstacle for treatment assuming that strict monitoring can be implemented 32. 
Although BZN is more commonly used than NF, both drugs seem to have similar efficacy 
and safety profiles. Reported treatment responses in the chronic indeterminate phase in children 
(mostly based on measuring serologic titers) are near 90% after NF treatment 33 and 94% for BNZ 
34,35. In adults NF has treatment response rate of 7-8% 36,37 and BZN between 2 and  40% 13,38, with 
more studies carried for BZN than NF in this area (see table 1). There are no current data formally 
comparing both drugs, but some clinical studies are currently ongoing attempting to address this 
issue, such as TESEO (NCT03981523)39. 
Unfortunately, given the natural history of CD and heterogeneity of response follow-up 
techniques, it is logistically challenging to treat this disease during the earlier asymptomatic 
chronic phase and follow that patient cohort to determine clinical outcomes, which can take 
decades to appear, with sufficient statistical power to differentiate potential effects in treated 
versus control patients. About 30 years ago two controlled placebo clinical trials assessed the 
efficacy of treatment in CD chronic phase in pediatric patients with good results35,40, and other 
studies followed those, leaving no doubt that the earlier children are treated, the better the 
response achieved8,40,41. Women in fertile age should also be treated to prevent congenital CD 
transmission9,40–42.  
Unlike treatment for children or women of reproductive age, controversies regarding 
treatment of adult patients still abound; in 2016 the first prospective multi-centric and 
randomized CD cohort study in older adults with advanced CD,  the `Benznidazole Evaluation for 
Interrupting Trypanosomiasis’ (BENEFIT), was published, describing the outcomes of  2854 
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patients with established Chagas heart disease that received BZN or placebo and were followed 
for 5.4 years13. This study concluded that no significant morbidity or mortality reduction was 
achieved with anti-parasitic treatment in patients with advanced cardiac stage. On the other side, 
the evidence from cohort and historical controlled trials has supported treating most chronic 
patients at early stages, with the available drugs16,43–47.  
Monitoring treatment is recommended for either drug, with complete blood counts, 
hepatic, and renal function testing. Frequency varies through different guidelines between every 




Brief Recent History  
Benznidazole (N- phenylmethyl-2-nitro-1H-imidazole-1-acetamide; CAS Number 22994-85- 
0) is the most commonly used drug for treatment of CD. It was developed by Roche (Ro 07-1051)49 
and there have been three producers of BZN so far: Roche, Lafepe (public pharmaceutical 
company of Brazil), and Chemo (formerly Elea, an Argentine pharmaceutical company). Roche 
manufactured and distributed the drug (as Radanil© or Rochagan©) from 1967 until the early 
2000s, when production was discontinued due to economic reasons49. Later, encouraged by 
pressure from scientific and medical organizations, Roche eventually transferred BZN production 
technology and remaining stocks to Lafepe, which committed to re-establish supply. Lafepe 
developed a pediatric formulation for children weighing < 20 kg (12.5 mg tablet) that was tested in 
clinical pediatric study in Argentina (sponsored by Drugs for Neglected Diseases initiative)8 and this 
formulation was registered in Brazil in 2011 and was included on the WHO’s Essential Medicines 
List for children in 2013.  
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BNZ was the first drug approved by the United States Food and Drug Administration (FDA) 
in 2017 for children ages two to twelve years with CD50,51 and in April 2018, a pediatric formulation 
of BZN was approved in Argentina to treat children under the age of 2 years. BZN is also prescribed 
off-label for adolescents, adults, and children under 2 in countries where the drug has not been 
registered specifically for these age groups.    
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BNZ Pharmacology  
Benznidazole is an oral, broad spectrum nitroimidazole antimicrobial that has activity 
against bacteria and several parasites. It has demonstrated efficacy against in vitro T. cruzi strains 
in several in vivo animal models 52–56. According to the Biopharmaceutical Classification System 
(BCS)57,58 BNZ belongs to Class IV drugs (reduced solubility and permeability); it is a liposoluble 
drug with very low solubility in water, and a weak base at physiological pH range. BNZ solubility in 
distilled water or simulated gastric and enteric fluids is reported between 0.2 mg/ml and 0.4 
mg/ml. According to this, BZN is classified as a low-permeability drug with a log P of 1.6458.  
BZN is considered a prodrug, requiring activation by parasite nitroreductase enzymes that 
reduce BZN, initiating a cascade of reactions leading to the formation of highly reactive drug 
metabolites27. The main parasite enzyme involved in BZN activation is believed to be a type 1 
nitroreductase. The resulting BZN metabolites, such as dialdehyde glyoxal, bind to parasite 
macromolecules disrupting T. cruzi metabolism and other vital functions, and leading to parasite 
cell death27. However, using a metabolomics approach to asses BZN mechanism of action, 
Trochine et al. proposed that the covalent binding of BZN with low molecular weight thiols as well 
as with protein thiols is a primary cause of the drug's toxicity against T. cruzi, instead of glyoxal 
generation as formerly stated59. This suggests that BZN acts in a complex manner and there are 
still some remaining uncertainties about its mechanisms of action: metabolomic studies are a 
promising frontier in this research area.  
T cruzi resistance to BZN is not well described in literature. Some in-vitro studies have 
reported that some parasite strains have a ‘natural’ in-vitro resistance to BZN associated with 
overexpression of ABCG transporter60, but this evidence has been questioned, as in-vitro results 
do not correlate with therapeutic outcomes in humans61. Other studies with in vitro data suggest 
that susceptibility of different T.cruzi strains to BZN fluctuates, but the 50% inhibitory 
concentration (IC50) values remain ≤19.5 μg/mL (75 μM) and can vary 10-fold within the same 
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assay. Activity against different forms of the parasite (epimastigotes, trypomastigotes, or 
amastigotes) also appears to vary within a relatively small range62,63, and it should be considered 
that many studies are performed on the epimastigote stage, which is easier to culture but not the 
human stage of the parasite. Additionally, time-kill studies indicate that BZN trypanocidal effect is 
both time and concentration dependent 62–64. Using multiple T.cruzi strains and a high-throughput 
screening platform, a rapid trypanocidal effect was demonstrated with 100% parasite clearance 
against multiple divergent T. cruzi genotypes, a rate superior to that for ergosterol biosynthesis 
inhibitors63.  
After oral administration, BZN is quickly absorbed from the human intestine (Ka = 1.14/h), 
with a plasmatic peak within 2–4 hours after drug intake8,65. The impact of food on absorption has 
not been systematically investigated. Some evidence points to first step elimination by hepatic 
biotransformation and entero-hepatic recirculation, possibly with some degree of enteric 
metabolism as well, but little research has been conducted in this area. Absolute bioavailability in 
humans has never been formally estimated due to the absence of an intravenous formulation apt 
for human use, though a mean relative oral bioavailability of 91.7% in three healthy adults when 
comparing liquid to solid oral formulations was reported66. Steady-state plasma concentrations are 
reached within 3 days of initiation of a twice-daily dosing regimen8,66. BZN distributes widely into 
tissues, including the central nervous system (CNS)67,68, with higher volume of distribution in 
children compared to adults8. The drug reaches CNS concentrations close to 70% of those 
observed in plasma, which has allowed successful treatment of Chagas CNS infections (e.g. 
meningoencephalitis) in immunosuppressed patients69–72. Plasma protein binding of BZN is 
approximately 50% and is thus not expected to lead to significant interactions with other drugs 54.  
Clearance of BZN is mainly by biotransformation (>80%) 68,73, believed to take place mostly 
in the liver, probably by members of the cytochrome P450 (CYP) family and/or tissue nitro-
reductases. However, few studies to date have explored the details of the metabolic pathways 
responsible for BZN elimination. Approximately 6–20% of the drug can be found unchanged in 
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urine, with differences depending on age of the patient (e.g., children seem to eliminate more 
unchanged drug in urine compared to adults); and the rest of the drug has been observed as 
reduced and conjugated.74 
Mean BZN half-life is 13 hours in adults66 and significantly shorter in children (3 to 6 hours 
for 2 to 7 year-old patients and 9 to 10 hours in children 7 to 12 years) as observed in two 
prospective clinical trials8. This difference in clearance and half-life between different age groups 
implies average steady-state concentrations of BZN lower in children than in adults. Interestingly, 
this difference does not seem to affect the efficacy of BNZ since in a prospective clinical trial, all 
treated children showed good response to treatment despite lower plasma concentrations of the 
drug8. When comparing the data obtained in this study with previously reported adult results66, a 
progressive decrease in the clearance rate of BZN with increasing age was observed (i.e. the older 
the patient, the slower the drug was eliminated). The specific mechanisms for drug elimination in 
children and adults remain undiscovered. Research in the area is actively testing different 
hypotheses such as slower drug metabolism in adults and impaired drug absorption in younger 
children. BNZ pharmacokinetics and treatment response in teenagers and young adults have never 
been studied, so the assumption that it would be in between children and adults is so far 
unsupported by actual evidence. 
The most commonly used BNZ dosing regimen, reported in the majority of the evidence 
published to date (see table 1) uses doses ranging from 5 to 8 mg/kg/day orally, in two daily doses 
for 30 to 60 days. BZN can also be administered in three daily doses, with a clear tendency in 
international guides for recommending 5 rather than 8 mg/kg/day and twice daily rather than 
thrice.48 
Duration of treatment in children and adults is currently under review and some expert 
guides are already recommending shorter treatments8,75, supported by the fact that treatment in 
children is proven to be effective despite differences in PK with adults leading to lower 
concentrations and shorter half-lives, without detectable drop in effectiveness and with less 
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adverse reactions8,75. A few trials enrolling children who received 30 days of treatment have 
showed good results42,76, and  recent evidence points towards possible efficacy of lower BNZ doses 
or less frequent dosing for adults and teenagers too65,77,78. Lower treatment duration has also 
proven to be effective in adults in preliminary results of an unpublished clinical trial 
(NCT03378661) that showed 89.3% of therapeutic response (measured as a negative PCR) after a 4 
week treatment compared to 82.8% after 8 week-treatment. There are currently other ongoing 
trials addressing BZN daily doses and duration as well such as BETTY trial79 and MULTIBENZ 
(NCT03191162), that may change treatment regimen in the next few years, assuming that 
sustained long term responses are demonstrated. 
The most commonly observed adverse drug reactions (ADRs) associated with BZN use 
include rash and pruritus, headache, myalgia, and gastrointestinal discomfort. Skin reactions 
characteristically appear between 7 to 12 days after the start of treatment. Drug-associated 
hepatitis, leucopenia, peripheral neuropathy, and severe drug hypersensitivity (Stevens-Johnson 
syndrome and other reactions with systemic symptoms) have also been reported but less 
frequently. The median proportion of severe side effects is 2.7%.45 Trough BZN serum 
concentrations did not appear to be related to the appearance of serious ADRs in a small study in 
adults80, but evidence for a concentration-adverse event relationship has been observed in 
pediatric studies8,34. A recent prospective study in 99 participants reported some previously 
unreported ADRs; ten subjects presented psychiatric symptoms (anxiety, panic attacks, emotional 
lability and persecutory delusions), four patients reported sexual alterations (erectile dysfunction 
or delay in menstrual cycle with no alternative explanations) and one patient had a bronchospasm. 
The results of this study were in other aspects similar to previously published literature about BZN 
adverse reactions.81 The safety profile of BZN in children is well described in the literature; data 
are consistent and do not suggest any signals of clinical concern8,34. 
The incidence of ADRs between children and adults has not been compared directly (i.e. in 
a study enrolling both age groups), but ADRs seem rare and almost universally mild in younger 
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children, and appear to increase gradually after 7 years of age in both frequency and severity. It is 
very infrequent to observe ADRs in newborns and children under 1 year old, and rates of 
treatment discontinuation due to ADRs are significantly low in children34,47,76,82–85 while these 
ranges between 11 and 45% in adult studies16,45,82,86. 
The underlying biological mechanisms for the observed ADRs have not been studied in 
depth, but the immune system seems to play an important role, particularly in the case of 
cutaneous rashes and hypersensitivity reactions. This assumption is based on the timing for the 
moderate cutaneous reactions (7–12 days after onset of treatment) that mimics the time course of 
similar reactions associated to other unrelated medications known to cause rash (e.g. lamotrigine), 
and the observation of rare severe adverse reactions such as Stevens-Johnson syndrome and drug 
reactions with eosinophilia and systemic symptoms83,84. A common immunological trigger for 
these reactions and possibly a pharmacogenetic predisposition could explain these similarities, but 
studies of potential pharmacogenomic markers are  missing. Some authors had formerly proposed 
to associate BZN with thioctic acid in order to prevent ADRs, based on this compound to increase 
hepatic elimination of BZN, but this has proven not to be effective when evaluated in-vivo.87 
BZN has never been formally studied during pregnancy, but it is not recommended for 
pregnant women due to the lack of safety data; there is insufficient information about 
reproductive safety of this drug, other than the fact that there have been no reports of 
malformations or any other pregnancy complications. However, it should be considered that it is 
likely that an unknown number of women were exposed to BZN in the first trimester by accident 
and the lack of reports on safety data might be a good sign so far. Also, there are some reports of 
treatment during late-stage pregnancy in emergency situations that did not result in any 
complications for the baby and may have saved the mother’s life69. The main recommendation 
therefore remains to avoid BZN during the first trimester of pregnancy and throughout pregnancy 
whenever possible until further information becomes available, though in case of an emergency or 
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a life-threatening situation caused by CD, we recommend not delaying treatment because of an 
unproven teratogenic risk69. 
BNZ has been classically contraindicated during lactation, but recent prospective studies 
and pharmacokinetic evaluations suggest that the risk of exposure to BZN from breastmilk for a 
breastfed baby is negligible, and lactation should not be considered a contraindication for CD 
treatment in those circumstances when treatment cannot be postponed. 29 
  




Brief Recent History 
NF was manufactured in the 1970s by Bayer -as Lampit®- but its development started 
earlier, in the 1960s as Bayer-2502. Similar to what happened with BZN, Bayer discontinued 
production in the 1990s due to low demand and almost null profitability, but reconsidered and 
restarted production later. Since then, country-level access to the drug has depended on individual 
states’ agreements and negotiations with WHO and Bayer, and local bureaucratic and political 
decisions. Availability currently seems erratic in many South American countries, but it is expected 
to improve in the near future, after a clinical trial performed in children -CHICO study 
(NCT02625974) - that supported FDA approval of NF formulations for CD in the pediatric 
population.   
 
 
Nifurtimox Clinical Pharmacology 
Many aspects of NF clinical pharmacology are similar to those of BZN. There is also 
considerable lack of knowledge on many aspects of its PK, effectiveness, and metabolism. 
However, NF is currently undergoing extensive redevelopment, with some clinical trials already 
completed and others in process (NCT04274101) (see table 1).  
NF mechanism of action is believed to be the generation of nitro-anion radicals, after 
activation by parasite nitroreductases in the presence of oxygen. This leads to production of free 
radicals that damage vital T. cruzi cell components, block DNA synthesis and accelerate DNA and 
RNA degradation88,89. 
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Similarly to BZN, NF is hydrophobic, highly liposoluble and distributes widely to tissues, 
including the central nervous system90, a useful property for the treatment of T. cruzi CNS 
infections. It has a rapid absorption from gut (Ka 0.77/h), but undergoes extensive first-pass 
elimination (much higher than BZN), leading to only a small fraction of orally administered NF 
reaching systemic circulation91,92. NF is administered orally and reaches peak plasma 
concentrations after 2 to 4 hours32,90,93 with a relatively short half-life (approximately 3 hours in 
adults, and similar in children based on very limited data)94,95. Liver elimination accounts for 
virtually all NF clearance (i.e., unchanged NF elimination in urine is less than 1% of the 
administered dose).96 
According to a recent trial that reported biopharmaceutical characteristics after oral 
administration of 30 mg and 120 mg tablets96, total systemic exposure to NF was approximately 
71% greater after food than in a fasted state. Mean (%CV) NF AUC estimates ranged between 
1676-2670 µg∙h/L (19–32%) and Cmax estimates ranged between 425-568 µg/L (26–50%) 
following administration of single dose 120 mg NF with food in adult CD patients. The median time 
to reach maximum concentration (Tmax) of NF under fed conditions was 4 hours (range: 2 to 8 
hours). Interestingly, in this study Cmax increased 68%, AUC increased 71%, and Tmax increased 
by 1 hour after a high-fat meal compared to fasted conditions.96 
Animal liver experiments of NF metabolism have suggested a number of metabolites97, but 
this aspect has only been studied in a limited number of humans, with preliminary confirmation of 
the metabolites observed in animal experiments and further observation of a range of minor 
metabolites98. Data from animal studies also suggests that CYP enzymes are responsible for NF 
metabolism, but no human data is publicly available identifying specific CYP isoforms, or 
associated enzymes, responsible for biotransformation98,99. NF plasma protein binding is 
approximately 50% and not expected to play a significant role in drug-drug interactions100. This 
drug is a substrate for the ABCG2 transporter, commonly known as Breast Cancer Resistance 
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Protein (BCRP), which has been shown to influence NF transport across the blood-brain barrier, as 
well as its excretion into breastmilk 30,31,101. 
NF apparent volume of distribution is high (V/F = 760 L), suggesting both an extensive 
distribution into tissues and also a significant pre-systemic elimination (i.e., a limited 
bioavailability), such as that observed in animal studies 91.  
Neither NF optimal dose nor the optimal treatment duration for CD is well defined. 
Initially, treatments tended to be long (90–120 days)102 but were subsequently reduced to mimic 
BZN treatment spans (approximately 60 days)103,104. The recent trial CHICO study (NCT02625974) 
studied alternative dosing (30 versus 60 days) observing similar serological and parasitological 
treatment responses for children under 2 years; but in order to apply these conclusions to all 
pediatric patients, long term follow-up would be crucial. Commonly used dose ranges from 8 to 15 
mg/kg/day divided in three daily administrations, but optimal daily dose frequency has never been 
duly studied either, and was defined only on the basis of NF half-life.  
The most commonly observed ADRs are anorexia and weight loss, irritability, sleepiness, 
and other nervous system signs and symptoms83,103,105. NF use is also associated with rash, 
pruritus, and drug-associated hepatitis but less frequently than BZN. Depression, peripheral 
neuropathy, and psychiatric symptoms have also been reported, less commonly. Similar to BZN, 
NF-associated ADRs seem much more common and severe in adults and are usually mild in 
children, including neonates96,106,107. Notably, there is some evidence that suggests that patients 
who develop a severe drug reaction to BZN may still be treated safely with NF 108.  
Similar to BZN, NF is considered contraindicated during pregnancy and lactation: virtually 
no data is available on the safety of this drug during the first trimester of pregnancy, and therefore 
it is still advisable to avoid its use at this stage. About lactation, recently published and ongoing 
studies on NF transfer into breastmilk strongly suggest that the drug is safe during breastfeeding, 
and treatment of a lactating mother should not be discouraged if needed30,31.  
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ASSESSMENT OF TREATMENT EFFICACY: EXISTING BIOMARKERS OF TREATMENT 
RESPONSE AND NEW ADVANCES 
The appropriate markers of CD cure (i.e. a patient being free from CD and not at risk of 
developing target organ involvement such as cardiomyopathy, cardiac failure,  mega-esophagus or 
mega-colon, etc.) have been subject to intense debate for decades, in part due to prolonged 
persistence of T.cruzi specific antibodies, lack of sensitivity of parasitological tests, and need for 
long-term follow-up (generally years or decades) to observe negative seroconversion of 
conventional serological tests, as well as a general lack of understanding of the parasite biology in 
the human and the kinetics of drug response. Serology (and, in particular, negative 
seroconversion) has been heralded for many years as the gold standard for treatment response, 
largely guided by the successful results observed after treating acute infections or early chronic 
infections in children8,109 (see table 1). However,  treatment of older patients, or even children 
over 7 years of age, does not lead to negative seroconversion for decades (if ever) 8,40,42,109, even if 
a drop in antibody titers is observed early after pharmacological treatment. This fact is easy to 
understand, if one considers that persistent immune system stimulation (e.g. as would be the case 
in chronic CD due to persistent antigen shedding by deep-tissue T cruzi nests) is bound to generate 
immune responses that would last for a long time even after complete parasite clearance by NF or 
BZN.  
Negative seroconversion continues to be the (somehow arbitrarily) chosen method to 
ascertain a treatment response, both in general practice and research. Reported serologic 
response rates are as high as 96% for congenitally infected infants 8,109–111, 76% for acute 
infections112, 63% 40,113 to 90% 113 for chronically infected children, and 37% for chronically infected 
adults 114. These rates have marked variability among different published studies due to different 
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serologic techniques employed, with sometimes poorly evaluated, different sensitivities and 
specificities, used to determine treatment response as the primary outcome of clinical trials115,116. 
It would be reasonable to consider that more sensitive serological techniques would 
under-estimate time and rates of cure (i.e. would yield positive antibody results with lower titers), 
with no correlation with clinical outcomes such as organ impact, but this still requires more 
research to confirm. In order to study the correlation between serologic response and organ 
damage, a recent study of a pediatric cohort performed a median after treatment follow-up of 10 
years of treated children with electrocardiograms (ECG), 24 hours ECG (Holter) and Speckle-
tracking strain echocardiography and observed no CD untoward impact on heart function in this 
population years after treatment, supporting the low correlation between serological tests and 
clinical response117.   Also, T. cruzi detection tests currently in use in some countries for long term 
follow up of patients such as polymerase chain reaction against T.cruzi-DNA (PCR) or different 
serology techniques, were initially developed for diagnostic purposes. Furthermore, many of the 
methods used have been repeatedly changed across the years, and comparison of results from 
recent clinical studies to older studies involves a degree of uncertainty even if comparing tests that 
are nominally the same (e.g. RT-PCR done in recent years would have used primers and protocols 
very different to those used 10 years ago) 41,46. In this context, new markers of cure are needed. 
Alternative early markers of cure have been suggested, such as decrease of total anti-T.cruzi 
antibody titers (i.e. instead of negative seroconversion) or use of non-conventional serological 
techniques 118,119 such as specific lytic anti-α-Gal antibodies known as anti-F2/3 antibodies120. 
Other CD biomarkers suggested by scientific literature so far have been reviewed by different 
authors too, but the general impression is that they all still require more research, and validation. 
Table 2 summarizes the biomarkers studied.46,121,122 
PCR has been proposed as a sensitive and specific method to detect T.cruzi parasitemia in 
newborns41,123,124 and has also shown good results for the assessment of treatment failure, as a 
persistently positive result after treatment clearly is evidence of failure to eliminate the 
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parasite125. However, while PCR may be more sensitive than current methods in some cases, the 
lack of standardization of the method across centers is a still unresolved issue. Furthermore, actual 
rate of false positives is still under debate, and may vary among testing laboratories (and different 
techniques used). Other issues such as cost and instrument availability and technical skills, 
conspire to limit the use of this method at the moment, but considering its good results so far and 
its feasibility of being easily applied in clinical settings, the investment in improving PCR 
methodologies is worthwhile. The CD community must focus on suitable strategies for parasite 
DNA extraction in lower sample volumes, the equivalence between blood and tissue parasitemia; 
the reduction of false negatives, as well as the validation and standardization of PCR assays; and 
the equivalence of PCR readouts with negative seroconversion.109,126–128 
Considering all available evidence, we could conclude that despite the need of trials in this 
area, a negative PCR -associated to a persistent decrease of T.cruzi antibodies titers- should be the 
chosen criteria used to assess treatment response and to follow-up after treatment in our time.  
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PHARMACOLOGICAL TREATMENT: NEW TREATMENT STRATEGIES AND 
ALTERNATIVE DRUGS  
As mentioned before, there are few recent advances in BZN and NF pharmacology, which 
is disappointing considering their longevity. Some improvements in drug formulation have been 
proposed (e.g.  application of nanotechnologies such as nanocrystals, polymeric nanoparticles, and 
lipid nanostructures) as an attractive approach to improve solubility and dissolution of BNZ and 
NFX, hopefully leading to dose reductions and, perhaps, novel treatment schemes, but virtually no 
clinical research has been undertaken with this proposed formulations 129,130.   
New potentially effective drugs have been proposed on the basis multiple targets in the 
parasite cell. Ergosterol biosynthesis enzymes in particular have been well studied, and CYP51 
(sterol 14-Demethylase) was proposed as an interesting target, both due to its importance in 
parasite survival, and the availability of multiple medications already in the market (i.e. azole 
antifungal drugs) that could be easily repositioned for clinical trials in CD 104,131–134. This 
repositioning approach is advantageous in view of the cost and time-consuming process required 
compared to the development of new medicines, especially in neglected diseases, since 
repositioned drugs already have their toxicological and pharmacokinetic profile assessed when 
used on their previous therapeutic target 135. Unfortunately, only allopurinol and a few azoles have 
been studied in clinical trials, observational studies, and case reports - there is an ongoing 
randomized double-blind, placebo controlled trial being carried (NCT03193749) comparing 
Amiodarone hydrochloride with placebo but there are no preliminary results disclosed so far. 
Despite allopurinol has shown to be useful in combination with NF or Benznidazole in small trials, 
evidence is still insufficient136–138. From azoles, posaconazole was compared in high and low doses 
versus placebo and research results concluded it has an acceptable antitrypanosomal activity, but 
also a significant increase in treatment failure compared with BZN group 139. Another randomized 
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placebo-controlled trial in adults tested E1224 (a ravuconazole pro-drug in different dosing 
regimens) and BZN versus placebo, and found that E1224 + BZN group displayed a transient, 
suppressive effect on parasite clearance, whereas BZN showed early and sustained efficacy until 
12 months of follow-up. This transitory effect was shown only in high dose sub-group while 
parasite levels in the low-dose and short-dose E1224 groups gradually returned to placebo levels 
140. In summary, from azole`s research, some former promising repositionable drugs such as 
monotherapy with ketoconazole, ravuconazole or posaconazole has not proven to be efficacious 
for the treatment of chronic T. cruzi infection 139–141 and the combination of posaconazole and BZN 
did not provide any further efficacy or safety advantages over BZN monotherapy 142,143. 
 Similarly, pre-clinical studies have identified interesting targets for drug action including 
cruzipain (parasite lysosomal cysteine), B citocrome, trypanothione reductase system, cyclophilins, 
N-myristoylome, carbonic anhydrases and NMDA glutamate receptor.143,144 However, none of 
these targets have drugs in clinical trials yet, and the ever-mounting costs of drug development 
and human clinical trials make it difficult to believe that many new molecules for CD would be 
coming into the market in the foreseeable future.  
Fexinidazole is a drug previously repositioned for Trypanosoma brucei gambiense infection 
(African trypanosomiasis) after demonstrating effectiveness in a randomized controlled trial 145. 
Also, fexinidazole`s safety and pharmacokinetics had been properly studied in humans, proving 
that oral administration is safe and well tolerated 132,133,146. Considering this drug is effective in 
clearing T.cruzi as well in pre-clinical studies, an ongoing randomized, double-blind, placebo 
controlled trial is being carried out in Argentina, Bolivia and Spain to assess its efficacy in CD 
(NCT02498782). 
Interestingly, some natural compounds and dietary supplements such as microalgae 
extracts147, wasp venom148, coumarins149, South American Vernonieae150,  curcumin151  and 
Resveratrol152  have been also studied for anti-tripanosomal activity, but more research is required 
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to draw conclusions, and there is still close to no human clinical data. The use of natural 
compounds to treat known diseases might lead to effective benefit-cost resources, considering 
that many of these compounds are not subject to patent restrictions and may be widely available. 
However, formal clinical testing should be performed before any of these compounds is used in 
patients.104   
In spite of a relative abundance of preclinical molecular candidates and potential 
repositionable drugs, there are currently no new classes of drugs in the clinical development 
pipeline for CD and BZN and NF remain the only two available drugs for treatment with relatively 
solid clinical data to support their use.      
Conclusion   
CD is a highly neglected tropical disease that has become an increasing worldwide 
problem in last decades. There is an alarming number of undiagnosed and untreated patients, and 
an urgent need for researchers and providers to change this fact. The choice for treatment 
remains between two drugs, created a century ago. The strongest data to support benefit-risk 
considerations come from trials in children (see Table 1).   
Scientific and economic effort should be urgently aimed to supply early diagnose and 
treatment in this population, in addition to more research in this area. New biomarkers for CD are 
strongly needed for the diagnosis and detection of treatment efficacy and efforts from academia 
and pharmaceutical companies to accelerate the process of new drugs development are 
necessary. Also, an extra effort to standardize a predictive Chagas disease in vivo model should be 
done and validated in order to improve its predictability and to ease its comparison and 
reproducibility.   
Early diagnosis and treatment of Chagas diseases, especially in pediatric patients, are vital 
for an effective and safe use of the available drugs (BZN and NF) medications.  
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Study Design Dosing Regimen Patients Therapeutic Effect Safety 
Moscatelli et 
al  2019 109 





cohort study,  
BZN:  5–8 mg/kg/day 
(mean 6.4 
mg/kg/day)  
bid (n= 76) or tid (n = 
31) 
Mean length 60 days  
107 enrolled 
91 completed 
After 3 year follow-up, PCR turned 
negative on 99% of patients. 
Out of 66 patients with initial 
positive F2/3-ELISA that 
completed: 72.7% became 
negative. (33.3% at end of 
treatment, 13.3% at 6 months, 
11.1% at 9 months, 8.9% at 26 
months, 20% at 36 months and 
13.4% at 42 months) 
Benznidazole was well tolerated 
and ADRs were mild, not 
requiring treatment suspension 
Robello et al. 
2019  
153 




BZN: 5 mg/kg per 
day for 60 days 
55 total (20 
enrolled/35 
completed) 
Infected children had higher fecal Firmicutes (Streptococcus, 
Roseburia, Butyrivibrio, and Blautia), and lower Bacteroides and also 
showed some skin -but not oral- microbiota differences. Treatment 
eliminated the fecal microbiota differences from control children, 
increasing Dialister (class Clostridia) and members of the 
Enterobacteriaceae, and decreasing Prevotella and Coprococcus, with 









BZN: 5 mg/kg per 
day for 60 days NF: 
10 mg/kg per day of 
for 60 days 





Treatment with BZN or NF 
induced a decline in T. cruzi-
specific IFN-g- and IL-2 
 Posttreatment changes in 
several of these markers 
distinguished children with a 
declining serologic response 
suggestive of successful 
treatment from those with 
sustained serological responses 
in a 5-year follow-up study. 
 
Mild ADRs were observed in 8 out 
of 40 (20%) subjects under 
treatment with BZN, while 5 
subjects (12.5%) showed severe 
ADRs that resulted in treatment 
suspension.  
Cutaneous rash and dermatitis 
were the main ADRs with BZN 
treatment, whereas NF was well 
tolerated. 
The five children who received 
incomplete BZN 
dosing were then treated with NF 
 
Table 1: Summary of relevant trials of Benznidazole and/or Nifurtimox in children  
This article is protected by copyright. All rights reserved
 
 
Altcheh et al. 
2014 
8 
IP* of CD* 2-12 
years of age (mean 







BZN: 5-8 mg/kg/day 
b.i.d. for 60 days 




All patients had negative T. cruzi 
PCR at Day 60 and at 1.5 year 
follow-up with decreased 
(compared to pre- treatment) T. 
cruzi antibody titers. 
 
Four (10%) patients had ADRs: 1 
mild rash, 1 moderate prurigo, 1 
generalized rash without systemic 
involvement, and 1 moderate 
eosinophilia. All ADRs subsided 
with symptomatic treatment and 
temporary drug discontinuation, 
and all patients recovered 
neventfully. 
Rumi et al. 
2013 
154 
IP* of CD* <16 years 
of age (range 3-15 
years) Argentina 
Clinical Trial 
BZN: 5 mg/kg/day 
b.i.d. for 60 days 





At 2-year follow-up (subset at 5-
year follow-up) almost no 
patient demonstrated ELISA 
seroconversion (however, 
approximately half with reduced 
titers) and almost all patients 
was PCR negative. 
Safety reported from 1 of 2 sites 
with 32 patients. ADRs in 30% of 
patients. Dermatological, 












BZN: 5 mg/kg/day 
b.i.d. for 60 days 
versus 7.5 
mg/kg/day once 
daily for 30 days  
(Radanil®) 
 
Tablets ground up 
and 8, 10, 13, and 15 
mg of powder filled 
into capsules. 








Microhematocrit method used 
for diagnosis (all positive pre-
treatment) for 1 and 2 month 
post-treatment follow-up (all 
negative).  
ELISA serology used at age 8-9 
months follow-up (all but 1 
patient negative). 
5 mg/kg/day: 38% of patients with 
ADRs. Primarily gastrointestinal 
and dermatological (5%-10% 
frequency).  
7.5 mg/kg/day: 31% of patients 




Tolerability similar for both 
treatment groups. Treatment 
temporarily stopped for most 
ADRs (<3 days) in both treatment 
groups. 
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Altcheh et al. 
2011 
34 
IP* of CD 10 days to 
19 years of age 




BZN: 5-8 mg/kg/day 
b.i.d. or t.i.d. for 60 
days (mean dose = 





administered in milk 
107 enrolled 
91 completed 
Treatment response was high 
and persistent, with over 90% of 
children who completed 60 days 
of treatment presenting a steady 
decrease or disappearance of 
specific T. cruzi antibodies and a 
negative parasitological test (T. 
cruzi–specific PCR and 
microhematocrit). 
No serious ADRs. 80.6% mild, 16% 
moderate, 3.2% severe 
(generalized rash). 7 patients 
(mostly older) discontinued due to 
ADRs.  41% had ADRs related to 
treatment: 
Dermatological = 21%  
CNS = 9 %  
Gastrointestinal = 9%  
Neuromuscular = 3%   
Clinical = 71%  
Laboratory changes = 29%  
No difference in safety profile by 
dosing regimen or gender, but 






with congenital CD 
***  Bolivia 
Clinical trial  
BZN: 2.5 mg/kg/day 
b.i.d. for 60 days 
(Group A) versus 7.5 
mg/kg/day once 
daily for 30 days 
(Group B) (Radanil®) 
tablets ground up 
and 8,10, 13 and 15 
mg of powder filled 
into capsules 
 
257 total  
Group A: 59 














Microhematocrit method used 
for diagnosis with parallel ELISA 
for following course of maternal 
versus newborn T. cruzi 
antibody titers. No significant 
difference between BZN 
treatment groups in time course 
or degree of reduction in ELISA 
titers.  
 
Approximately 90% of treated 
newborns had negative ELISA 
serology by month 10. 
No safety results reported. 
This article is protected by copyright. All rights reserved
 
 
Escriba et al. 
2009 
156 
IP* of CD <13 years 
(28%<5 years)  
Honduras 
45% male  
Clinical trial 
BZN: 7.5 mg/kg/day 







27 followed for 
an additional 
1.5 years. 
Serology decrease of 75% or 
more compared to baseline at 
18-month follow up: 88.2% (13 
of 27)  
 
48.1% that remained 
seropositive at 18-month follow-
up were seronegative at 36-
month follow-up. 
No serious ADRs. Most ADRs mild 
or moderate. 3 patients 
temporarily discontinued 
treatment due to severe adverse 
event (neurological).  
Gastrointestinal = 27% 
Dermatological = 13% 
Neurological = 10%   
No difference in safety profile by 
dosing regimen or gender, but 
greater frequency in older 
patients. 
Yun et al. 
2009 
83 
IP of CD <18 years of 
age.  
Honduras = <12 
years  
Guatemala = <15 
years   






mg/kg/day b.i.d. or 
t.i.d. for 60 days 
(source of drug 
product not stated 
but given Roche 
product was only 
BZN available at the 
time, this is 
assumed). 












Serology seroconversion to a 
negative result at 18 months 
post-treatment: 
Honduras = 87.1 % 
Guatemala = 58.1% 
 Bolivia (rural) = 5.4 % 
 Bolivia (peri-urban) = 0 % 
Honduras: 
ADRs = 50% of patients; 97% mild, 
0% moderate, 3% severe (latter all 
neuromuscular-related). 
Gastrointestinal = 27% 
Dermatological = 13% 
Neurological = 10% 
Guatemala: 
ADRs = 51% of patients; 81% mild, 
14% 
moderate, 5% severe. 
Dermatological = 26% 
Gastrointestinal = 25% 
Neuromuscular = 23% 
Other = 26% 
Chavez et al. 
2006 
157 





BZN: 8 mg/kg/day 
for 60 days (drug 




At 14-month follow-up 96% 
were still sero-positive on ELISA 
(75% of patients showed a 
decreased antibody titer of>50% 
at 12-month follow-up) and 68% 
were positive on PCR 
No safety results reported. 
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Streiger et al 
2004 
33 




BZN: 5 mg/kg/day 




days b.i.d or t.i.d 
 
(Source of drug 
product not staten) 







Serology seroconversion to a 
negative result at any point of 
follow up: 
NF: 6/7 (85,7%)  
BZN: 23/37 (62,2%)  
Untreated children did not 
change the serology 
 
75% of treated children became 
negative when treated at ≤4 
years old and 43% when treated 
at ≥9 years old.  
 
 
NF: anorexia, weight-loss, hepatic 
enlargement slighty painfully, mild 
hepatic and renal toxicitiy (clinical 
or laboratory findings) 
  
BZN: vomiting, mild rash. 2 







IP* of CD <17 years 
divided by age of 
initiation of therapy: 
● 0-6 months of 
age 
● 7 months-17 
years of age 
Argentina 
Clinical trial 
NF (Lampit®) 10–15 
mg/kg/day or BZN: 
(Radanil®)         5-8 
mg/kg/day b.i.d. for 




10 < 3 months 
of age 
6 from 7 
months-2 
years of age 
24 >3 years of 
age 
Percentage of patients at 2-3-
year follow-up with 
seroconversion (positive to 
negative): 
 
<3 months of age = 100% 
7 months-2 years of age = 67% 
>3 years of age = 13% 
No safety results reported. 
Galvao et al 
2003 
35,158 
IP* of CD (range 7-





BZN: 5-7 mg/kg/day 
b.i.d. for 60 days 
versus placebo 
127 (64 BZN / 
65 placebo) 
PCR was applied to a cohort of T. 
cruzi-seropositive children who 
had been exposed to BZN 
chemotherapy or placebo 3 
years earlier  
PCR at baseline: 84.2% positivity 
Untreated patients had a 1.6-
fold-higher chance of remaining 
PCR positive (34 of 53 versus 23 
of 58) than those who had 
received BZN 
No safety results reported. 




et al 2003 
159 
IP* of CD 
0-10 years of age 
Chile 
Clinical trial 
NF (Lampit®): 10 
mg/kg/day for 30 
days 
99 
100% negative xenodiagnose, 
100% negative PCR after 3 year 
follow-up 
95,3% well tolerated. 4,7% mild 
nauseas. None interrupted.  
Solari et al. 
2001 
160 
IP* of CD*  0-10 
years  
Chile 
Clinical trial NF: Not shown 66 
34/36 positive serology at 36 
months follow-up, 100% 
negative xernodiagnose and PCR 
No safety results reported. 
Solari et al 
1998 
161 




NF: 7 mg/kg/day 60 
days 
28 
100% negative xenodiagnose, 
35.8% negative PCR 




IP* of CD (range 6-






BZN: 5 mg/kg/day 




55 BZN / 51 
placebo 
Seroconversion to a negative 
result after 48 months with 
conventional serology:   
BZN:11.3% (5 of 44)  
Placebo: 4.5% (2 of 44)  
 
Seroconversion to a negative 
result with F29 EIA increased 
from 35.7% to 62.1% six and 48 
months, respectively, after 
treatment.  
No placebo-treated child 
seroconverted to a negative 
result by the end of follow-up 
 
Less than 20% of participants 
reported ADRs that included 
intestinal colic, cutaneous 
maculopapular rush, headache, 
anorexia, vomiting, nausea, 
diarrhea, dizziness, paresthesia, 
and light shivering of the hands. 
During treatment only intestinal 
colic and rush were more frequent 
in the BZN group than in the 
placebo group, appearing at days 
11.3 and 19.5, respectively. No 
severe ADRs were reported. Six 
(10%) of 55 in the BZN group had 
moderate ADRs. 
De Andrade 
et al 1996 
35 
De Andrade 
et al 2004 
113 
IP* of CD (range 7-
12 years at 
enrollement and 14-








BZN: 5-7 mg/kg/day 






Seroconversion to a negative 
result  
After 3 years follow up: 
BZN: 58% (37 of 64)  
Placebo: 5% (3 of 65) 
Efficacy of BZN by intention to 
treat:55.8% 
After 6 years follow up: 
BZN: 88.7% (47 of 53), 
Placebo: 26.1% (12 of 46) 
Efficacy of BZN by intention to 
treat: 64.7% 
Minor ADRs requiring no specific 
medication were recorded in a 
small proportion of individuals 
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Biomarker type Biomarker Results in Chagas disease References 
Parasite proteins 
Trypomastigotes F2/3 antigenic fraction 
Anti F2/3 decreases after BZN treatment and disappears 
after 4–21 months in children 
120 
Immunofluorescence assay of fixed 
trypomastigotes (ISIFA) 
High titers in infected patients and low titers 6 years 
after treatment when patients were considered cured. 
High sensitivity and no cross-reactivity with other 
diseases 
112,162 
Trypomastigote mucin antigen A&T CL-
ELISA 
Measure anti-Gal Abs. Titers decrease after BZN 




Ag13 85 kDa protein with repeats of 5 
amino acids 
Anti-Ag13 is suitable for CD diagnosis in different 
populations, and titers decrease and disappear after 3 
years posttreatment 
165  
T. cruzi ribosomal acid protein P2β 
Levels of Anti-P2β decrease in asymptomatic treated CD 
patients 
166 
Immunodominant antigens KMP11, 
HSP70, PFR2, Tgp63 
A significant drop in reactivity against antigens between 
6 and 9 months in BZN treated CD adults at different 
stages of the disease. Titers continue to drop after 24 
months 
167,168 
24 kDa calcium-binding protein (rTc24) 
Anti-rTC24 Abs decreases within 6–36 months post-
treatment 
169,170 
Flagellar calcium-binding protein (F29) 
Sero-reversion for the F29 antigen occurs between 6 and 
48 months after BZN treatment in children 
40,119 
Multiplex 16 r T. cruzi proteins 
Decreased response of the panel 36 months after BZN 
treatment in adults 
118,171 
Recombinant complement regulatory 
protein (rCRP) 
Detect Abs complement-dependent as the CoML test. 
Positive reactions decrease 1–2 years after BZN 
treatment 
172 
Table 2: Candidate Chagas disease surrogate biomarkers. Modified from the book Chagas disease, a clinical approach, Freilij, H., Altcheh, J., 
(Chapter Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities, Ruiz-Lancheros et al.) 
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Putative microtubule-associated protein 
(MAP) antigen3 
Selected antigen from a multiplex array of 15 antigens 
Results correlate with PCR-positive and PCR-negative 









ApoA1 and FBN fragments 
Upregulated in CD and downregulated after BZN or NFX 
treatments 
174,175 
Lytic antibody complement-mediated 
lysis (CoML) test 
Abs decreases until becoming negative after parasite 




Prothrombin fragment 1 + 2 (F1 + 2) 
A marker of thrombin generation in vivo increases early 
in CD and decreases after BZN treatment 
176,177 
Endogenous thrombin potential (ETP) 
Quantifies the ability to generate thrombin when 
activated through tissue factor addition upregulated in 
CD, decreases after BZN treatment 
176,177 
Soluble platelet selectin 
(sP-selectin) 
Biomarker of in vivo platelet activation decrease during 




IFN-γ T cells 
Three-fold decrease compared with pretreatment 
between 1 and 3 years posttreatment 
12 
CD3+ T cells 
CD3+ T-cell proportion differs between treated and 
untreated patients and normalizes in cured patients 
179 
IL12+ CD14+ cells 
BZN-treated children show low levels of IL12+ CD14+ 
cells and high levels of IL-10 modulated type 1 cytokines 
profile 
180 
CD4+ LIR+ T cells 
Decrease of CD4+ LIR+ T cells after treatment between 2 
and 6 months and for at least 2 years 
47,181 
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